Literature DB >> 7679727

Characterization of a human NK1 tachykinin receptor in the astrocytoma cell line U 373 MG.

E Heuillet1, J Ménager, V Fardin, O Flamand, M Bock, C Garret, A Crespo, A M Fallourd, A Doble.   

Abstract

The human NK1 tachykinin receptor in the astrocytoma cell line U 373 MG was characterized using selective agonists and antagonists described for this receptor in the rat. Specific [3H]substance P binding sites were present on cell homogenates, whereas [3H]neurokinin A or [3H]-senktide binding sites were absent. The binding was saturable and reversible. The binding of [3H]substance P was inhibited by very low concentrations of [L-Pro9]substance P and [Sar9,Met(O2)11]substance P; septide was approximately 1,000-fold less potent. The most potent peptide antagonist was trans-4-hydroxy-1-(1H-indol-3-ylcarbonyl)-L-prolyl-N-methyl-N-(phe nylmethyl)-L- tyrosineamide. The rank order of potency for the nonpeptide antagonists was (S,S)-CP 96,345 > (+/-)-CP 96,345 > (+/-)-2-chlorobenzylquinuclidinone > (R,R)-CP 96,345 > RP 67580 > RP 68651. In [3H]-inositol-labeled cells, substance P stimulated phosphatidylinositol turnover. A good correlation was found when the abilities of NK1 receptor agonists for stimulating inositol phosphate production and for inhibiting [3H]substance P binding were compared. Similarly, the binding and functional assays were well correlated for the antagonists. As a result of its high sensitivity and selectivity, the U 373 MG cell line thus appears an excellent tool for investigating the pharmacology of the human NK1 receptor.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 7679727     DOI: 10.1111/j.1471-4159.1993.tb03231.x

Source DB:  PubMed          Journal:  J Neurochem        ISSN: 0022-3042            Impact factor:   5.372


  6 in total

1.  Interactions between tachykinins and diverse, human nicotinic acetylcholine receptor subtypes.

Authors:  R J Lukas; C M Eisenhour
Journal:  Neurochem Res       Date:  1996-10       Impact factor: 3.996

2.  The pharmacology of GR203040, a novel, potent and selective non-peptide tachykinin NK1 receptor antagonist.

Authors:  D T Beattie; I J Beresford; H E Connor; F H Marshall; A B Hawcock; R M Hagan; J Bowers; P J Birch; P Ward
Journal:  Br J Pharmacol       Date:  1995-12       Impact factor: 8.739

3.  Mitigation of Oxidation in Therapeutic Antibody Formulations: a Biochemical Efficacy and Safety Evaluation of N-Acetyl-Tryptophan and L-Methionine.

Authors:  Michelle Z Dion; Danielle Leiske; Vikas K Sharma; Christina L Zuch de Zafra; Cleo M Salisbury
Journal:  Pharm Res       Date:  2018-10-02       Impact factor: 4.200

4.  Substance P induces rapid and transient membrane blebbing in U373MG cells in a p21-activated kinase-dependent manner.

Authors:  John Meshki; Steven D Douglas; Mingyue Hu; Susan E Leeman; Florin Tuluc
Journal:  PLoS One       Date:  2011-09-23       Impact factor: 3.240

5.  Anti-tumour activity of tachykinin NK1 receptor antagonists on human glioma U373 MG xenograft.

Authors:  C Palma; M Bigioni; C Irrissuto; F Nardelli; C A Maggi; S Manzini
Journal:  Br J Cancer       Date:  2000-01       Impact factor: 7.640

6.  Substance P activates responses correlated with tumour growth in human glioma cell lines bearing tachykinin NK1 receptors.

Authors:  C Palma; F Nardelli; S Manzini; C A Maggi
Journal:  Br J Cancer       Date:  1999-01       Impact factor: 7.640

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.